Prostaglandin EP2 receptor: Novel therapeutic target for human cancers (Review)

Int J Mol Med. 2018 Sep;42(3):1203-1214. doi: 10.3892/ijmm.2018.3744. Epub 2018 Jun 26.

Abstract

Prostaglandin E2 (PGE2) receptor 2 subtype (EP2), which is a metabolite of arachidonic acid that binds with and regulates cellular responses to PGE2, is associated with numerous physiological and pathological events in a wide range of tissues. As a stimulatory G protein‑coupled receptor, PGE2‑induced EP2 activation can activate adenylate cyclase, leading to increased cytoplasmic cAMP levels and activation of protein kinase A. The EP2 receptor can also activate the glycogen synthase kinase 3β and β‑catenin pathways. The present study aimed to review the roles of the EP2 receptor in tumor development, including immunity, chronic inflammation, angiogenesis, metastasis and multidrug resistance. Furthermore, the involvement of the EP2 receptor signaling pathway in cancer was discussed. Understanding the role and mechanisms of action of the EP2 receptor, and its importance in targeted therapy, may help identify novel methods to improve management of numerous types of cancer.

Publication types

  • Review

MeSH terms

  • Cyclic AMP / metabolism
  • Cyclic AMP-Dependent Protein Kinases / metabolism
  • Dinoprostone / genetics
  • Dinoprostone / metabolism*
  • Humans
  • Neoplasms / genetics
  • Neoplasms / metabolism*
  • Receptors, Prostaglandin E, EP2 Subtype / genetics
  • Receptors, Prostaglandin E, EP2 Subtype / metabolism*

Substances

  • Receptors, Prostaglandin E, EP2 Subtype
  • Cyclic AMP
  • Cyclic AMP-Dependent Protein Kinases
  • Dinoprostone